<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>lyso-Gb3 &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/lyso-gb3/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 03:20:07 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>lyso-Gb3 &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Enzyme Replacement Therapy Proves Safe and Stable in Chinese Patients with Fabry Disease</title>
		<link>https://bioengineer.org/enzyme-replacement-therapy-proves-safe-and-stable-in-chinese-patients-with-fabry-disease/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 03:20:07 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[agalsidase alfa]]></category>
		<category><![CDATA[alpha-galactosidase A]]></category>
		<category><![CDATA[anti-drug antibodies]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Enzyme Replacement Therapy]]></category>
		<category><![CDATA[Fabry disease]]></category>
		<category><![CDATA[Gb3]]></category>
		<category><![CDATA[lyso-Gb3]]></category>
		<category><![CDATA[lysosomal storage disease]]></category>
		<category><![CDATA[Pharmacokinetics]]></category>
		<category><![CDATA[phase 3 trial]]></category>
		<category><![CDATA[rare disease]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=424583</guid>

					<description><![CDATA[A 52-week phase 3 trial across six Chinese centers found agalsidase alfa was generally well tolerated, kept kidney and cardiac measures stable, and produced sustained reductions in lyso-Gb3 in treatment-naive patients with Fabry disease.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">424583</post-id>	</item>
	</channel>
</rss>
